How should we incorporate molecular data in treatment decisions for ALL? It is time to pay more attention to genetic heterogeneity of adult ALL before we decide therapy. Targeted therapies are rapidly emerging, and replacing chemo in ALL. Our review at Blood Cancer Discovery is out today! Link👇

We are very excited to share our work investigating menin inhibition in T-ALL, led by Kate Shimamoto and Arda Karaoglu, just published in Mol Cancer Therapeutics. We found that high p-MEF2C S222 can predict menin inhibitor response, better than HOX gene expression levels, in T-ALL. rb.gy/oroosm

very cool work led by @canersaygin.bsky.social lab looking at the potential for targeting menin in T-cell ALL! aacrjournals.org/mct/article/...

In a recent study, Caner Saygin, MD and team examined a large group of adults with a rare, aggressive form of leukemia called TP53-mutant ALL and found key genetic changes that guide doctors to predict which pts may face more serious outcomes. @uchicagomedicine.bsky.social https://ow.ly/cFsz50YgL2s

InO + TKI has robust activity but limited toxicity when drugs are given sequentially. Great option for older adults with Ph+ ALL in frontline.

Our NCI study of HMA +/- Iadademstat is enrolling briskly for patients with HMA-naive accelerated/blast phase MPNs and overlap syndromes! www.cancer.gov/research/par...

In a new study, @canersaygin.bsky.social and colleagues show that TP53-mutant ALL is a high-risk, chemo-resistant subtype with poor survival, highlighting the need for tailored strategies. ow.ly/lvwo50WHJIr

We’re thrilled to announce the 2025–2027 New Investigator Research Grant recipients—13 outstanding scientists from across the country who are pushing the boundaries of leukemia research. Meet the 2025–2027 awardees: bit.ly/474sfGP #LeukemiaResearch #ScientificDiscovery #FundingtheFuture

Proud of our cancer program for being #1 in Illinois for the 3rd year in a row!! Learn more about our USNWR rankings at www.uchicagomedicine.org/forefront/ne...

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with @uchicagocancer.bsky.social myeloma program. www.nature.com/articles/s41...